Prospects of the first human glucagon-like peptide 1 analog liraglutid use in the treatment of patients with type 2 diabetes mellitus
Liraglutid is the first representative of human glucagon-like peptide-1 (GLP-1) analogs. The article presents data for the mechanisms of liraglutid action and review of studies on the efficacy and safety of its use in patients with type 2 diabetes mellitus (type 2 diabetes). Based on the research results, liraglutid administration in doses of 1.2/1.8 mg once daily resulted in significant and sustained glycemic control improvement, and also was accompanied by a number of additional effects, such as a persistent decrease in body weight, clinically significant decrease of systolic blood pressure level and improvement of of beta-cells function. Thus, new class of human GLP-1 analogs provides a unique opportunity in the treatment of type 2 diabetes mellitus, providing pathogenetic influence on progressive reduction of beta-cell function, and factors of cardiovascular risk.